Solara Q2 FY27: Consolidated Swings to ₹28.5 Cr Profit, Revenue +33% YoY, Margins Expand
revenue +33.1% · margins expanding · beat vs street
₹417.34 Cr
+33.1% YoY
₹28.46 Cr
6.81%
+10pp YoY
₹5.92
Solara Active Pharma's consolidated Q2 FY27 (quarter ended September 30, 2026) print shows a swing to ₹28.46 Cr net profit from a ₹10.10 Cr loss in the year-ago quarter, on revenue up 33.1% YoY to ₹417.34 Cr (from ₹313.54 Cr); sequentially revenue grew 9.4% and PAT rose 74.5% QoQ from Q1 FY27's ₹16.31 Cr. The result beat our pre-result preview range on every metric — revenue (₹380-400 Cr expected vs ₹417.34 Cr actual), EBITDA margin (16-18% 'at risk' range vs 18.41% actual), and PAT sustainability (₹14-16.5 Cr expected vs ₹28.46 Cr actual) — and no independent analyst consensus for this specific quarter turned up beyond that preview's Street read (average 12-month target ₹715-720, ratings split Hold/Buy). Against management's own prior guidance of 'at least 10% YoY growth,' the 33.1% YoY revenue gain is a clear beat; the targeted 25% base-business EBITDA margin cannot be directly verified this quarter since the filing discloses only one reportable segment (API) with no base-vs-Ibuprofen split, though blended consolidated OPM of 18.41% is the strongest of the three quarters shown (11.08% year-ago, 16.24% last quarter).
Q2 FY-2027 vs prior quarters
The reported PAT carries a ₹4.50 Cr one-time exceptional loss on sale of capital work-in-progress tied to the mothballed Vizag plant; stripped out, core PBT was ₹32.96 Cr against a ₹10.10 Cr loss a year ago — the underlying turnaround is larger than the headline number, since this quarter's one-off was itself a drag rather than a boost (the year-ago quarter had no exceptional item to compare against). NPM improved to 6.82% from -3.22% YoY, tracking the OPM expansion. Net debt fell by roughly ₹114 Cr during H1 FY27 to about ₹546 Cr (consolidated borrowings less cash & bank balances), consistent with the stated path to zero net debt by FY29, even as H1 capex of ₹54.83 Cr already consumed nearly all of the ₹55-60 Cr full-year FY27 capex guidance in just two quarters. Management's own filing notes cite 'improvement in business performance, anticipated growth in revenues and margins' and adequate resources to meet obligations on a going-concern basis, directionally consistent with the print. Two in-quarter developments tie to the numbers: a tax rectification order dropped a prior demand, removing a contingent overhang, and the ongoing rights-issue call-money collection (₹446.62 Cr of ₹449.95 Cr raised per filing note 7) explains the movement in paid-up equity; the Crisil ESG upgrade to 63 ('Strong') is non-financial. Management's H1 FY27-timed conclusion on the Ibuprofen strategic review — guided to carry a ₹10-15 Cr quarterly EBITDA drag — is not referenced anywhere in this filing and remains unresolved heading into Q3.
The stock went into the print at ₹717, up 0.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
EPS (basic) ₹5.92 for the quarter vs ₹3.52 in Q1 FY27 and -₹2.36 in Q2 FY26
Base business targeting 25% EBITDA margin (±1%) and at least 10% YoY growth. Net debt reduction on track to zero by FY29. FY27 capex ₹55-60 Cr (40% debottlenecking). Ibuprofen strategic review conclusion expected H1 FY27; expecting ₹10-15 Cr quarterly EBITDA loss going forward.
— This quarter: beat
W1
Ibuprofen strategic review conclusion, guided for H1 FY27 (just ended) and carrying a ₹10-15 Cr quarterly EBITDA drag — not addressed in this filing; watch for resolution in Q3 commentary
W2
Net debt trajectory toward the FY29 zero-debt target, given H1 capex of ₹54.83 Cr already near the full ₹55-60 Cr FY27 budget
W3
Whether the ₹4.50 Cr Vizag CWIP write-off was a one-time item or the start of further mothballed-asset write-downs
Consolidated PBT (28.46) includes a ₹4.50 Cr exceptional loss on sale of Vizag plant CWIP (mothballed since FY23-24); PBT before exceptional was ₹32.96 Cr. Year-ago quarter had no exceptional item (PAT -10.10 was core). Tax nil both periods (large accumulated losses: ₹274.16 Cr consolidated). EPS is not annualised for the quarter. Deloitte-reviewed, clean text PDF, columns unambiguous.
Informational and educational content only. Not investment advice.